The Economic Times

Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study

The study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have little to no detectable cancer in the prostate at the time of surgery compared with those given testosterone-blocking therapy alone.